icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
7yVZnHVKswB6rPxs